Elevated serum ferritin is associated with increased mortality in non‐alcoholic fatty liver disease after 16 years of follow‐up
- 28 April 2016
- journal article
- Published by Wiley in Liver International
- Vol. 36 (11) , 1688-1695
Abstract
Background & Aims: High levels of ferritin in patients with non‐alcoholic fatty liver disease (NAFLD) are associated with significant fibrosis and higher NAFLD activity score (NAS). It is unclear if this association has an impact on mortality. We investigated if high levels of ferritin, with or without iron overload, were associated with an increased mortality in NAFLD.Methods: We included 222 patients between 1979 and 2009 with biopsy‐proven NAFLD and available serum ferritin concentrations. The cohort was divided into ‘high’ (n = 89) and ‘normal’ (n = 133) ferritin values, using a cut‐point of 350 μg/L in males, and 150 μg/L in females, and stratified upon iron overload status. Data on mortality were obtained from a national, population‐based register. Poisson regression was used to estimate hazard ratios for mortality. The estimates were adjusted for age at biopsy, sex, smoking, BMI, diabetes, hypertension, cardiovascular disease and fibrosis stage at the time of biopsy.Results: The median follow‐up time was 15.6 years (range: 0.5–34.2). Patients with high ferritin had more advanced fibrosis and higher NAS than patients with normal ferritin (P < 0.05). Fifteen years after diagnosis, and after adjusting for confounders, the high‐ferritin group showed an increasingly higher mortality that was statistically significant (Hazard ratio = 1.10 per year, 95% Confidence interval 1.01–1.21, P < 0.05). There was no difference in mortality between patients with different iron overload patterns.Conclusions: High levels of ferritin are associated with a long‐term increased risk of death.Keywords
Funding Information
- Stockholms Läns Landsting (20140329, 20150403)
- American Liver Foundation
This publication has 27 references indexed in Scilit:
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐upHepatology, 2014
- Cohort Study of Non-alcoholic Fatty Liver Disease, NAFLD fibrosis score, and the Risk of Incident Diabetes in a Korean populationAmerican Journal of Gastroenterology, 2013
- The global NAFLD epidemicNature Reviews Gastroenterology & Hepatology, 2013
- Prevalence of Nonalcoholic Fatty Liver Disease in the United States: The Third National Health and Nutrition Examination Survey, 1988–1994American Journal of Epidemiology, 2013
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United StatesHepatology, 2012
- Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menaceJournal of Hepatology, 2012
- Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adultsAlimentary Pharmacology & Therapeutics, 2011
- the Incidence and Risk Factors of Hepatocellular Carcinoma in Patients With Nonalcoholic SteatohepatitisHepatology, 2010
- Non-alcoholic fatty liver disease and increased risk of cardiovascular diseaseAtherosclerosis, 2007
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡Hepatology, 2006